Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna SBC by award type
SBC by award type — Performance stock units (PSUs) ($M) ($M)
Moderna SBC by award type: $4M in Q2 2026, up 100.0% from a year earlier. That is the highest of the 10 quarters on record here.
Latest, Q2 2026
4
Period ended Jun 30, 2026
Change on a year earlier
+100.0%
2 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 14 (Stock-Based Compensation).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SBC by award type — Performance stock units (PSUs) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 4 | +100.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 3 | +200.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 3 | -200.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 2 | 0.0% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 2 | -33.3% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 1 | -66.7% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | -3 | – | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 2 | – | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 3 | – | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 3 | – | Form 10-Q (filed 2025-05-01) ↗ |
Cite this data
StockData. (2026). Moderna SBC by award type ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/sbc-psus
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.